Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Raxibacumab

Monoclonal antibody · Antagonist of Bacillus anthracis protective antigen · developed by Human Genome Sciences

Approved FDA, Dec 2012
1 Registered trials

What is Raxibacumab?

Raxibacumab is a monoclonal antibody that binds the protective antigen of Bacillus anthracis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
Bacillus anthracis protective antigen
Mechanism
Antagonist of Bacillus anthracis protective antigen
Therapy area
Infectious disease
Developer
Human Genome Sciences Inc.
In trials of
EBS
FDA status
Approved (December 14, 2012), BLA125349 · FDA label
UNII
794PGL549S

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02339155 Phase 4 Infections, Bacterial Completed EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Infections, Bacterial

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.